Lexeo Therapeutics (LXEO) analyst forecast and price target
Analyst forecast
Consensus of 9 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $9.00 from $12.00 | Jun 25, 2026 |
| Chardan Capital | Maintained | Buy | $17.00 | May 11, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $13.00 | Jan 13, 2026 |
| Chardan Capital | Maintained | Buy | $17.00 | Jan 13, 2026 |
| Raymond James | Initiated Coverage | Strong Buy | $25.00 | Dec 18, 2025 |
| Chardan Capital | Maintained | Buy | $17.00 | Dec 11, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $19.00 | Dec 1, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $19.00 | Nov 20, 2025 |
| Chardan Capital | Maintained | Buy | $17.00 | Nov 5, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $15.00 | Oct 21, 2025 |
| Guggenheim | Initiated Coverage | Buy | $30.00 | Oct 15, 2025 |
| Leerink Partners | Maintained | Outperform | $20.00 from $9.00 | Oct 7, 2025 |
| Chardan Capital | Maintained | Buy | $17.00 from $15.00 | Oct 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $9.00 | Oct 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $9.00 from $15.00 | Aug 15, 2025 |
| Chardan Capital | Maintained | Buy | $15.00 from $20.00 | Aug 15, 2025 |
| Oppenheimer | Initiated Coverage | Outperform | $20.00 | Jul 31, 2025 |
| JP Morgan | Maintained | Overweight | $10.00 from $16.00 | May 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $23.00 | May 16, 2025 |
| Chardan Capital | Maintained | Buy | $20.00 from $22.00 | May 13, 2025 |
Frequently asked questions
Is LXEO a buy, sell, or hold?
Analysts covering Lexeo Therapeutics currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on LXEO?
On Jun 25, 2026, JP Morgan maintained Lexeo Therapeutics at Overweight with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.